Scientists at the V Foundation for Cancer Research unveiled three distinct breakthroughs this week, offering new hope for patients with hard-to-treat cancers. The discoveries, presented at the Krzyzewski Family Cancer Research Symposium, span genetically engineered immune cells, canine cancer studies, and a non-invasive test for pediatric brain tumors.
The most ambitious approach involves turning the body's own immune system into a targeted weapon. Dr. Ami Bhatt described how her lab is using precise, DNA-pasting enzymes to modify normal T cells, transforming them into cancer-killing CAR-T cells. Rather than relying on traditional chemotherapy, this technique essentially reprograms a patient's white blood cells to recognize and attack malignancies. Bhatt noted that her team is borrowing strategies from the most evolved organisms on earth, a concept she calls turning biologies into therapies. Early results suggest this method could make CAR-T therapy more effective and accessible for patients who have exhausted other options.
A second project is exploring the striking similarities between canine and human cancers. Dr. Robert Canter reported that dogs develop many of the same tumor types as humans and respond to treatment in nearly identical ways. His lab is currently testing natural killer (NK) cell therapy in dogs, with the goal of improving immunotherapy outcomes for both species. Because canine trials can move faster than human studies, researchers say this approach could accelerate the timeline for bringing new immune-based treatments to patients. The work also offers a direct benefit to veterinary medicine, giving pet owners access to cutting-edge therapies.
A Blood Test for Pediatric Brain Tumors
The third breakthrough addresses a devastating gap in pediatric oncology. Brain tumors remain the number one cause of cancer deaths in children, and diagnosis often requires invasive surgical biopsies. Dr. Shannon Stott is changing that. Her laboratory now receives blood samples from pediatric patients at multiple cancer centers across the country. Using these samples, her team has developed a blood test that can detect brain tumor signals without surgery. This allows doctors to monitor tumor status, track treatment response, and detect recurrence far earlier. For families, the test provides both better treatment guidance and peace of mind, sparing children from repeated invasive procedures.
The symposium also reinforced the broader mission behind these efforts. Susanna Fletcher Greer, Chief Scientific Officer at the V Foundation, reminded attendees of the late Jim Valvano's famous words: cancer research is our only hope for a cure. She emphasized that each of these projects began with a simple question, and that the researchers presenting today are turning that hope into measurable progress.
Looking ahead, all three research teams plan to expand their trials. Bhatt aims to refine the DNA-editing process for broader patient use, Canter is preparing larger canine studies that could inform human protocols, and Stott is working to validate her blood test across more pediatric cancer centers. While a cure remains years away, these parallel efforts represent a coordinated push toward less invasive, more personalized, and ultimately more effective cancer care.